Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a glowing iPad screen help reset your body clock?

NCT ID NCT07744711

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study looks at how adults use an iPad-based app that delivers light to support the body's internal clock, which controls daily rhythms in sleep and alertness. Participants use the app for up to eight weeks while doing normal activities like reading or watching videos, and answer short questions about sleep and their experience. Some may also choose to wear a device to track movement and light, or give samples for optional biomarker analysis. The goal is to understand usage patterns and user feedback, not to test whether the app treats any medical condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iPad-based light-delivery app (Circadian OS / KairOS)
What this could lead to
If successful, this could help refine light-based tools to support daily rhythms in sleep and alertness for people who don't get enough consistent bright light.
What could go wrong
This is a small, early observational study, not a treatment trial. It won't prove the app improves health, and results may not apply beyond the specific group of participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult 18 years of age or older * Able to read, understand, and provide written informed consent in English * Has access to a compatible iPad capable of running the study app for the duration of the exposure period, or is willing to use a Sponsor-supplied iPad * U.S. resident, able to be in the NYC metropolitan area for the study * Member of the Sponsor's network (friends, family, advisors, investors, employees, or contractors) * If opting in to the biomarker sub-study: weighs at least 110 lb (50 kg), and meets standard venipuncture eligibility on the day of collection Exclusion Criteria: * Diagnosed bipolar disorder, or history of light-induced manic or hypomanic episodes * Pregnant, attempting to become pregnant, or breastfeeding * Diagnosed photosensitivity disorder, retinal disease, or use of medications known to cause significant photosensitivity, at investigator discretion based on disclosed medications * Currently using prescription light therapy, or actively enrolled in another light-related research study * Unable to consent for themselves (participants requiring enrollment by a legally authorized representative are not eligible) * Biomarker sub-study only: acutely unwell, febrile, or reporting acute infectious symptoms on the study day * Biomarker sub-study only: known bleeding diathesis, anticoagulant use other than low-dose aspirin, severe needle phobia, or whole-blood or plasma donation within the prior two weeks * Biomarker sub-study only: member of the study or laboratory team who would otherwise process their own sample * Any condition that, in the judgment of the investigator or attending phlebotomist or nurse, would make participation unsafe

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circadian rhythms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • SOSV

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.